Real-World Oncological Outcomes of Nivolumab Plus Ipilimumab in Advanced or Metastatic Renal Cell Carcinoma: A Multicenter, Retrospective Cohort Study in Japan

Real-World Oncological Outcomes of Nivolumab Plus Ipilimumab in Advanced or Metastatic Renal Cell Carcinoma: A Multicenter, Retrospective Cohort Study in Japan

A combination of nivolumab and ipilimumab (NIVO + IPI) is the only approved combination of two immune checkpoint inhibitors for metastatic or advanced renal cell carcinoma (mRCC). Inadequate evidence of treatment with NIVO + IPI has been reported in Japanese cohorts. We evaluated the clinical effica...

Full description

Saved in:
Bibliographic Details
Main Authors: Tomoki Taniguchi, Koji Iinuma, Kei Kawada, Takashi Ishida, Kimiaki Takagi, Masayuki Tomioka, Makoto Kawase, Kota Kawase, Keita Nakane, Yuki Tobisawa, Takuya Koie
Format: Article
Language:English
Published: MDPI AG 2024-12-01
Series:Current Oncology
Subjects:
renal cell carcinoma
nivolumab
ipilimumab
Japanese cohort
Online Access:https://www.mdpi.com/1718-7729/31/12/583
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items